Nuvera, J&J's Veridex Ink Deal to Develop, Market Breast Cancer Drug Response Dx

Terms of the deal call for Nuvera to run clinical trials to validate the assays, which gauge treatment response to tamoxifen and taxane-containing chemotherapies, and for Veridex to validate, launch, and market the tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories